Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wen Xiong

Rheumatology Vauxhall, NJ Medical Doctor

NPI 1447408216 CMS profile 110506

2280 Springfield Ave, Vauxhall, NJ 07088

Open in the dashboard

General payments

$48,885

1,112 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wen Xiong of Vauxhall, NJ is reported in the CMS Open Payments database as having received $48,885 across 1,112 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,530 161
2024 General $6,732 172
2023 General $14,767 163
2022 General $10,877 138
2021 General $6,069 139
2020 General $1,475 126
2019 General $2,434 213

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wen Xiong
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Wen Xiong were reported at $6,530. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Wen Xiong Rheumatology median Middle half National median
2019 $2,434 $744 $153–$2,687 $163
2020 $1,475 $462 $98–$2,027 $114
2021 $6,069 $531 $101–$2,153 $132
2022 $10,877 $627 $125–$2,303 $149
2023 $14,767 $741 $145–$2,524 $160
2024 $6,732 $830 $166–$2,660 $164
2025 $6,530 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $33,727 65 payments
  2. AbbVie, Inc. $2,414 176 payments
  3. Janssen Biotech, Inc. $1,937 109 payments
  4. Amgen Inc. $1,538 127 payments
  5. Pfizer Inc. $1,341 116 payments
  6. UCB, Inc. $1,022 73 payments
  7. Novartis Pharmaceuticals Corporation $869 54 payments
  8. ANI Pharmaceuticals, Inc. $778 41 payments
  9. E.R. Squibb & Sons, L.L.C. $625 62 payments
  10. GlaxoSmithKline, LLC. $560 34 payments
  11. Other $4,074 255 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,380 13 payments
  2. Food and Beverage $16,612 1,082 payments
  3. Consulting Fee $6,000 1 payment
  4. Travel and Lodging $2,358 5 payments
  5. Education $535 11 payments
Products named General payments · program years 2019–2025
  1. OFEV Respiratory $16,741 27 payments
  2. OFEV Respiratory $4,079 20 payments
  3. TREMFYA $1,808 89 payments
  4. RINVOQ $1,607 116 payments
  5. XELJANZ $1,235 105 payments
  6. Cimzia $777 56 payments
  7. ORENCIA $625 62 payments
  8. HUMIRA $483 37 payments
  9. PURIFIED CORTROPHIN GEL $480 22 payments
  10. BENLYSTA $421 32 payments
  11. Other $9,001 605 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

5,940

Median for Rheumatology: 1,511

Drug cost

$3,148,738

Median for Rheumatology: $1,139,948

Branded share of claims

21.7%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cortrophin Corticotropin Brand 14 $811,978
Enbrel Sureclick Etanercept Brand 74 $598,795
Humira(Cf) Pen Adalimumab Brand 55 $483,819
Humira(Cf) Adalimumab Brand 21 $229,683
Xeljanz Tofacitinib Citrate Brand 35 $209,663
Rinvoq Upadacitinib Brand 30 $200,521
Xeljanz Xr Tofacitinib Citrate Brand 19 $111,386
Actemra Actpen Tocilizumab Brand 26 $109,666
Actemra Tocilizumab Brand 20 $78,238
Humira Pen Adalimumab Brand 11 $76,538

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$58,241

Of which drugs: $1,913

Medicare patients

142

Average age 71

Services billed

1,321

122 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 50%
Ischemic heart disease 34%
Chronic kidney disease 34%
Osteoporosis 26%
Heart failure 25%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 33 234 $183

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
$3,956 — —
TREMFYA
$606 — —
RINVOQ
$352 30 —
PURIFIED CORTROPHIN GEL
$301 — —
Cimzia
$117 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

1,112 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record